RESUMEN
The interaction of sperm with the oocyte is pivotal during the process of mammalian fertilization. The limited numbers of sperm that reach the fallopian tube as well as anatomic restrictions indicate that human sperm-oocyte encounter is not a matter of chance but a directed process. Chemotaxis is the proposed mechanism for re-orientating sperm toward the source of a chemoattractant and hence to the oocyte. Chemokines represent a superfamily of small (8-11 kDa), cytokine-like proteins that have been shown to mediate chemotaxis and tissue-specific homing of leukocytes through binding to specific chemokine receptors such as CCRs. Here we show that CCR6 is abundantly expressed on human sperms and in human testes. Furthermore, radioligand-binding experiments showed that CCL20 bound human sperm in a specific manner. Conversely, granulosa cells of the oocyte-surrounding cumulus complex as well as human oocytes represent an abundant source of the CCR6-specific ligand CCL20. In human ovaries, CCL20 shows a cycle-dependent expression pattern with peak expression in the preovulatory phase and CCL20 protein induces chemotactic responses of human sperm. Neutralization of CCL20 in ovarian follicular fluid significantly impairs sperm migratory responses. Conversely, analyses in infertile men with inflammatory conditions of the reproductive organs demonstrate a significant increase of CCL20/CCR6 expression in testis and ejaculate. Taken together, findings of the present study suggest that CCR6-CCL20 interaction may represent an important factor in directing sperm-oocyte interaction.
Asunto(s)
Quimiocina CCL20/genética , Infertilidad Masculina/genética , Oocitos/fisiología , Receptores CCR6/genética , Interacciones Espermatozoide-Óvulo/genética , Espermatozoides/fisiología , Quimiocina CCL20/antagonistas & inhibidores , Quimiocinas/metabolismo , Quimiotaxis , Femenino , Líquido Folicular/metabolismo , Fase Folicular/fisiología , Regulación de la Expresión Génica/genética , Células de la Granulosa/metabolismo , Humanos , Inmunohistoquímica , Masculino , Análisis por Micromatrices , Receptores CCR6/antagonistas & inhibidores , Espermatozoides/metabolismo , Testículo/metabolismoRESUMEN
Over the past years aesthetic procedures have been evolving as an important part of daily dermatological practice. Herein, fillers represent an integral component of a modern, multimodal aesthetic treatment approach. Advances in the understanding of the aging face and modern fillers offer a broad variety of indications ranging from augmentation to hydration or collagen-induction. At the same time the range of available injection materials, products and techniques has grown to mere unmanageable dimensions. Finally, dermatologists are frequently confronted with the consequences of improper filler treatments or late side effects of early filler materials which have already disappeared from the market and even the experienced injector may encounter treatment-associated side effects. Here, we review the most important current and historic filler materials, including indications, injection techniques, adverse effects and the respective management recommendations.
Asunto(s)
Técnicas Cosméticas , Envejecimiento de la Piel , Materiales Biocompatibles , Estética , Ácido Hialurónico , InyeccionesRESUMEN
BACKGROUND: Photodynamic therapy with daylight (DL-PDT) is efficacious in treating actinic keratosis (AK), but the efficacy of field-directed, repetitive DL-PDT for the treatment and prophylaxis of AK in photodamaged facial skin has not yet been investigated. METHODS/DESIGN: In this multicenter, prospective, randomized, controlled, two-armed, observer-blinded trial, patients with a minimum of 5 mild-to-moderate AK lesions on photodamaged facial skin are randomly allocated to two treatment groups: DL-PDT with methyl aminolevulinate (MAL) and cryosurgery. In the DL-PDT group (experimental group), 5 treatments of the entire face are conducted over the course of 18 months. After preparation of the lesion and within 30 min after MAL application, patients expose themselves to daylight for 2 h. In the control group, lesion-directed cryosurgery is conducted at the first visit and, in the case of uncleared or new AK lesions, also at visits 2 to 5. The efficacy of the treatment is evaluated at visits 2 to 6 by documenting all existing and new AK lesions in the face. Cosmetic results and improvement of photoaging parameters are evaluated by means of a modified Dover scale. Primary outcome parameter is the cumulative number of AK lesions observed between visits 2 and 6. Secondary outcome parameters are complete clearance of AK, new AK lesions since the previous visit, cosmetic results independently evaluated by both patient and physician, patient-reported pain (visual analogue scale), patient and physician satisfaction scores with cosmetic results, and patient-reported quality of life (Dermatology Life Quality Index). Safety parameters are also documented (adverse events and serious adverse events). DISCUSSION: This clinical trial will assess the efficacy of repetitive DL-PDT in preventing AK and investigate possible rejuvenating effects of this treatment. (Trial registration: ClinicalTrials.gov Identifier: NCT02736760). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02736760 . Study Code Daylight_01. EudraCT 2014-005121-13.
Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Criocirugía , Queratosis Actínica/tratamiento farmacológico , Queratosis Actínica/cirugía , Fotoquimioterapia , Adulto , Ácido Aminolevulínico/uso terapéutico , Femenino , Humanos , Análisis de Intención de Tratar , Queratosis Actínica/prevención & control , Masculino , Proyectos de Investigación , Método Simple Ciego , Luz SolarAsunto(s)
Condiloma Acuminado , Verrugas , Acetamidas , Condiloma Acuminado/tratamiento farmacológico , Humanos , Morfolinas , Pomadas , PiridinasRESUMEN
The molecular changes in gene expression following ablative laser treatment of skin lesions, such as atrophic scars and UV-damaged skin, are not completely understood. A standardized in vitro model of human skin, to study the effects of laser treatment on human skin, has been recently developed. Therefore, the aim of the investigation was to examine morphological and molecular changes caused by fractional ablative erbium:YAG laser treatment on an in vitro full-thickness 3D standardized organotypic model of human skin. A fractional ablative erbium:YAG laser was used to irradiate organotypic human 3D models. Laser treatments were performed at four different settings using a variety of stacked pulses with similar cumulative total energy fluence (60 J/cm2). Specimens were harvested at specified time points and real-time PCR (qRT-PCR) and microarray studies were performed. Frozen sections were examined histologically. Three days after erbium:YAG laser treatment, a significantly increased mRNA expression of matrix metalloproteinases and their inhibitors (MMP1, MMP2, MMP3, TIMP1, and TIMP2), chemokines (CXCL1, CXCL2, CXCL5, and CXCL6), and cytokines such as IL6, IL8, and IL24 could be detected. qRT-PCR studies confirmed the enhanced mRNA expression of IL6, IL8, IL24, CXCLs, and MMPs. In contrast, the mRNA expression of epidermal differentiation markers, such as keratin-associated protein 4, filaggrin, filaggrin 2, and loricrin, and antimicrobial peptides (S100A7A, S100A9, and S100A12) as well as CASP14, DSG2, IL18, and IL36ß was reduced. Four different settings with similar cumulative doses have been tested (N10%, C10%, E10%, and W25%). These laser treatments resulted in different morphological changes and effects on gene regulations. Longer pulse durations (1000 µs) especially had the strongest impact on gene expression and resulted in an upregulation of genes, such as collagen-1A2, collagen-5A2, and collagen-6A2, as well as FGF2. Histologically, all treatment settings resulted in a complete regeneration of the epidermis 3 days after irradiation. Fractional ablative erbium:YAG laser treatment with a pulse stacking technique resulted in histological alterations and shifts in the expression of various genes related to epidermal differentiation, inflammation, and dermal remodeling depending on the treatment setting applied. A standardized in vitro 3D model of human skin proved to be a useful tool for exploring the effects of various laser settings both on skin morphology and gene expression during wound healing. It provides novel data on the gene expression and microscopic architecture of the exposed skin. This may enhance our understanding of laser treatment at a molecular level.
Asunto(s)
Láseres de Estado Sólido/uso terapéutico , Modelos Biológicos , Piel/efectos de la radiación , Biomarcadores/metabolismo , Diferenciación Celular/efectos de la radiación , Quimiocinas/genética , Quimiocinas/metabolismo , Niño , Dermis/efectos de la radiación , Proteínas Filagrina , Regulación de la Expresión Génica/efectos de la radiación , Humanos , Terapia por Láser/métodos , Masculino , Análisis de Secuencia por Matrices de Oligonucleótidos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Estándares de Referencia , Cicatrización de Heridas/efectos de la radiaciónRESUMEN
In the past decades many new drugs were approved for the treatment of cancer and have been established as essential parts of various therapeutic regimens. In particular targeted therapies and immune checkpoint inhibitors that aim at specific carcinogenic signaling pathways or modulate the tumor-immune response have revolutionized cancer therapy. Despite their targeted actions, these drugs may lead to diverse adverse reactions. In particular, cutaneous toxicities represent a serious threat to patients' quality of life and may lead to dose reduction or therapy cessation. In most cases, basic management is performed by the treating oncologist. Nevertheless, more severe reactions may require the expertise of a dermatologist. In this review, we present specific cutaneous adverse reactions of new drug classes such as epidermal growth factor receptor inhibitors (EGFR-I), multikinase inhibitors (MKI), BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors (anti-PD1-, anti-CTLA4-antibodies). Furthermore, we give recommendations concerning the prevention and management of respective cutaneous reactions.
Asunto(s)
Antineoplásicos/efectos adversos , Antineoplásicos/clasificación , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/terapia , Diagnóstico Diferencial , Erupciones por Medicamentos/etiología , Medicina Basada en la Evidencia , Humanos , Resultado del TratamientoRESUMEN
OBJECTIVE: Chronic hard-to-heal wounds generate high costs and resource use in western health systems and are the focus of intense efforts to improve healing outcomes. Here, we introduce a novel native collagen (90 %):alginate (10 %) wound dressing and compare it with the established oxidised dressings Method: Matrices were analysed by atomic force microscopy (AMF), scanning electron microscopy (SEM), and immunoelectron microscopy for collagen types I, III and V. Viability assays were performed with NIH-3T3 fibroblasts. Matrix metalloproteinase (MMP) binding was analysed, and the effect of the wound dressings on platelet-derived growth factor B homodimer (PDGF-BB) was investigated. RESULTS: Unlike oxidised regenerated cellulose (ORC)/collagen matrix and ovine forestomach matrix (OFM), the three-dimensional structure of the native collagen matrix (NCM) was found to be analogous to intact, native, dermal collagen. Fibroblasts seeded on the NCM showed exponential growth whereas in ORC/collagen matrix or OFM, very low rates of proliferation were observed after 7 days. MMP sequestration was effective and significant in the NCM. In addition, the NCM was able to significantly stabilise PDGF-BB in vitro. CONCLUSION: We hypothesise that the observed microstructure of the NCM allows for an effective binding of MMPs and a stabilisation and protection of growth factors and also promotes the ingrowth of dermal fibroblasts, potentially supporting the re commencement of healing in previously recalcitrant wounds. DECLARATION OF INTEREST: This work was supported by BSN Medical, Hamburg, Germany.
Asunto(s)
Vendajes , Colágeno/farmacología , Cicatrización de Heridas/fisiología , Animales , Bovinos , Supervivencia Celular , Celulosa Oxidada/farmacología , Colágeno/ultraestructura , Fibroblastos/fisiología , Fibroblastos/ultraestructura , Metaloproteinasas de la Matriz/metabolismo , Microscopía de Fuerza Atómica , Microscopía Electrónica de Rastreo , Microscopía Inmunoelectrónica , Agregación Plaquetaria , Proteínas Proto-Oncogénicas c-sis/metabolismo , Oveja DomésticaRESUMEN
BACKGROUND: The introduction of molecularly targeted anticancer therapies presents new challenges, among which dermatologic adverse events are noteworthy. Alopecia in particular is frequently reported, but the true incidence is not known. PATIENTS AND METHODS: We sought to ascertain the incidence and risk of developing alopecia during treatment with approved inhibitors of oncogenic pathways and molecules [anaplastic lymphoma kinase, breakpoint cluster region-abelson, B-rapidly accelerated fibrosarcoma, Bruton's tyrosine kinase, cytotoxic T-lymphocyte antigen-4, epidermal growth factor receptor, human epidermal growth factor receptor-2, Janus kinase, MAPK/ERK (extracellular signal-regulated kinase) Kinase, mammalian target of rapamycin, smoothened, vascular endothelial growth factor, vascular endothelial growth factor receptor, platelet derived growth factor receptor; proteasomes; CD20, CD30, CD52]. Electronic database (PubMed, Web of Science) and ASCO meeting abstract searches were conducted to identify clinical trials reporting alopecia. Meta-analysis was conducted utilizing fixed- or random-effects models. RESULTS: The calculated overall incidence of all-grade alopecia was 14.7% [95% confidence interval (CI) 12.6% to 17.2%]-lowest with bortezomib, 2.2% (95% CI 0.4% to 10.9%), and highest with vismodegib, 56.9% (95% CI 50.5% to 63.1%). There was an increased risk of all-grade alopecia [relative risk (RR), 7.9 (95% CI 6.2-10.09, P ≤ 0.01)] compared with placebo, but when compared with chemotherapy, the risk was lower [RR, 0.32 (95% CI 0.2-0.55, P ≤ 0.01)]. CONCLUSIONS: Targeted therapies are associated with an increased risk of alopecia.
Asunto(s)
Alopecia/inducido químicamente , Antineoplásicos/efectos adversos , Terapia Molecular Dirigida/efectos adversos , Alopecia/diagnóstico , Antineoplásicos/administración & dosificación , Ensayos Clínicos como Asunto/métodos , Humanos , Neoplasias/diagnóstico , Neoplasias/tratamiento farmacológicoRESUMEN
BACKGROUND: The introduction of pegylated interferon (PEG-IFN)-α in the treatment of chronic hepatitis C has led to an increase in sustained virological response. Despite reduced immunogenicity of the pegylated form in comparison with native interferon (IFN)-α, a high frequency of adverse cutaneous reactions has been reported with pegylated IFN-α. Here, we aimed to investigate the immunological mechanisms underlying pegylated IFN-α-induced drug eruptions. METHODS: Hepatitis C patients suffering from drug eruptions in association with administration of pegylated interferons were enrolled in the study (n = 22). Subjects were tested for sensitivity to pegylated IFN-α2a , pegylated IFN-α2b , or ribavirin using intradermal, scratch, and/or patch tests, as well as lymphocyte activation tests (LATs). Skin biopsies obtained from pegylated IFN-α-associated exanthemas, as well as from localized inflammatory skin reactions at pegylated IFN-α injection sites, were analyzed for the expression of relevant chemokines by quantitative real-time PCR and immunohistochemistry. RESULTS: A subset of patients suffering from pegylated IFN-α-associated exanthemas displayed positive intradermal tests to PEG-IFNs but not to conventional IFN (11/22). In selected patients, this observation correlated with the presence of pegylated IFN-specific T cells (3/11). Chemokine profiles of inflammatory skin reactions at the injection sites reflected an IFN-α-signature, whereas lesional skin of exanthemas showed induction of TH2-associated chemokines. CONCLUSIONS: Our results indicate that specific sensitizations are one cause of exanthemas under therapy with PEG-IFNs. Clinical proof-of-concept analyses demonstrate that affected patients may benefit from a switch to conventional, nonpegylated drugs, enabling IFN-α therapy continuation without drug-associated skin eruptions.
Asunto(s)
Antivirales/efectos adversos , Erupciones por Medicamentos/etiología , Interferón-alfa/efectos adversos , Polietilenglicoles/efectos adversos , Antivirales/uso terapéutico , Citocinas/genética , Citocinas/metabolismo , Erupciones por Medicamentos/diagnóstico , Expresión Génica , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/tratamiento farmacológico , Humanos , Factores Reguladores del Interferón/genética , Factores Reguladores del Interferón/metabolismo , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Activación de Linfocitos , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Piel/patología , Pruebas Cutáneas , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismoRESUMEN
The BRAF inhibitor vemurafenib was approved in 2011 for the treatment of inoperable or metastatic melanoma. Vemurafenib therapy is associated with several side effects, such as arthralgia, secondary skin tumors or inflammatory rashes. In particular cutaneous toxicities represent a serious threat to patients' adherence. Here, we present the case of a successful drug desensitization in a patient that presented with a vemurafenib-induced rash. Lymphocyte activation tests failed to detect drug-specific T cells, suggesting that the development of the rash was based upon a nonallergic drug hypersensitivity reaction. A program of slow desensitization was initiated and subsequently, vemurafenib was tolerated at the full effective and recommended dosage.
Asunto(s)
Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/prevención & control , Exantema/inducido químicamente , Indoles/administración & dosificación , Indoles/efectos adversos , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Desensibilización Inmunológica/métodos , Relación Dosis-Respuesta a Droga , Erupciones por Medicamentos/diagnóstico , Exantema/diagnóstico , Exantema/prevención & control , Femenino , Humanos , Persona de Mediana Edad , Resultado del Tratamiento , VemurafenibRESUMEN
Condylomata acuminata (CA) are one of the most common sexually transmitted infections in the sexually active population. Due to the stigmatizing character of the disease and the high rate of relapse after therapy, CA may significantly affect patients' quality of life. Here, we report the case of successful treatment of multiple CA of the penis and scrotum in a 53-year-old man with ingenol mebutate gel.
Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Condiloma Acuminado/patología , Diterpenos/administración & dosificación , Enfermedades del Pene/tratamiento farmacológico , Enfermedades del Pene/patología , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Juggling is a highly interesting tool to investigate neuroplasticity associated with motor-learning. Several brain-imaging studies have reported changes in regional brain morphology in visual association cortices in individuals learning how to juggle a three-ball cascade. However, to our knowledge there are no studies that investigated expert jugglers, looking for specific features in regional brain morphology related to this highly specialized skill. Using T1-weighted images and voxel-based morphometry we investigated in a cross-sectional study design 16 expert jugglers, able to juggle at least five balls and an age- and gender-matched group of non-jugglers. We hypothesized that expert jugglers would show higher gray matter density in regions involved in visual motion perception and eye-hand coordination. Images were pre-processed and analyzed using SPM8. Age was included in the analyses as covariate of no interest. As compared to controls jugglers displayed several clusters of higher, regional gray matter density in the occipital and parietal lobes including the secondary visual cortex, the hMT+/V5 area bilaterally and the intraparietal sulcus bilaterally. Within the jugglers group we also found a correlation between performance and regional gray matter density in the right hMT+/V5 area. Our study provides evidence that expert jugglers show increased gray matter density in brain regions involved in visual motion perception and eye-hand coordination, i.e. brain areas that have previously been shown to undergo dynamic changes in terms of gray matter increases in subjects learning a basic three-ball cascade. The extent to which transient increases in beginners and the differences in experts and non-experts are based on the same neurobiological correlates remains to be fully elucidated.
Asunto(s)
Mapeo Encefálico , Encéfalo/anatomía & histología , Encéfalo/fisiología , Sustancia Gris/anatomía & histología , Desempeño Psicomotor/fisiología , Adulto , Estudios Transversales , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Imagen por Resonancia Magnética , Masculino , Percepción de Movimiento/fisiología , Percepción Visual/fisiología , Adulto JovenRESUMEN
Ingenol mebutate is a novel cytotoxic drug extracted from the plant Euphorbia peplus. Since November 2012 it is approved in Germany for the treatment of superficial actinic keratoses. We report the successful treatment of Bowen disease with ingenol mebutate in a patient being treated with the multikinase inhibitor sunitinib for to metastatic clear cell renal carcinoma.
Asunto(s)
Enfermedad de Bowen/tratamiento farmacológico , Enfermedad de Bowen/patología , Diterpenos/administración & dosificación , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Anciano , Antineoplásicos/administración & dosificación , Humanos , MasculinoRESUMEN
A 54-year-old man presented for the removal of a professional tattoo on the right upper arm. We initiated a comparative treatment with a q-switched 694-nm Ruby laser (TattooStar® Effect, Asclepion® Lasertechnologies, Jena, Germany, Spot: 4 mm, Fluence: 4 J/cm(2)) using the so-called R20-method. The tattoo was divided into three equal parts and was treated with up to three passes in one session at intervals of 20 min. After 3 sessions, which were conducted at intervals of 4 weeks, the areas that had been treated with multiple passes per session showed a significantly stronger fading compared to the area that had been treated with single passes. The patient reported a slight, transient blistering in the area that had been treated with three passes. Nevertheless, we did not observe any scarring or other irreversible complications. Our observation demonstrates the efficacy of the R20-method for the laser-removal of tattoos.
Asunto(s)
Terapia por Luz de Baja Intensidad/métodos , Piel/efectos de la radiación , Tatuaje , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
The use of hyaluronic acid fillers for treatment of rhytides (wrinkles) is widespread in aesthetic dermatology and is considered a safe procedure; however, complications can occur especially if the injections are carried out by an inexperienced person and/or with a lack of anatomical knowledge. The two cases presented here exemplify this problem. In conclusion, both cases demonstrate complications after uncritical injection of hyaluronic acid fillers into "risk" or "expert" regions. While the patients in these two cases recovered completely, the injection of filler substances can also lead to the risk of potentially permanent side effects, such as granuloma, necrosis with scar tissue formation and even blindness. The frequency and severity of complications often show a direct correlation with the qualification or expertise of the person treating and hence injection treatments should be performed solely by physicians.
Asunto(s)
Absceso/inducido químicamente , Erupciones por Medicamentos/etiología , Dermatosis Facial/inducido químicamente , Ácido Hialurónico/efectos adversos , Viscosuplementos/efectos adversos , Absceso/diagnóstico , Absceso/terapia , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/terapia , Dermatosis Facial/terapia , Femenino , Humanos , Ácido Hialurónico/administración & dosificación , Inyecciones Intradérmicas , Persona de Mediana Edad , Envejecimiento de la Piel/efectos de los fármacos , Viscosuplementos/administración & dosificaciónRESUMEN
In recent years, several new classes of compounds have successfully been established in the treatment of cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects of these anticancer agents include cutaneous reactions and occur in a time-dependant manner and show class-specific patterns. In this review article, we compare the cutaneous side effects of epidermal growth factor inhibitors (EGFRI), multikinase inhibitors (MKI), BRAF inhibitors (BRAFI), mTor inhibitors (mTorI) and immune checkpoint inhibitors and discuss severity-adapted management strategies.
Asunto(s)
Antineoplásicos/efectos adversos , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/prevención & control , Terapia Molecular Dirigida/efectos adversos , Erupciones por Medicamentos/etiología , HumanosRESUMEN
BACKGROUND AND OBJECTIVE: Large intestinal fermentation of dietary fiber may control meal-related glycemia and appetite via the production of short-chain fatty acids (SCFA) and the secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). We investigated whether this mechanism contributes to the efficacy of the Roux-en-Y gastric bypass (RYGB) by assessing the effect of oligofructose-enriched inulin (inulin) vs. maltodextrin (MDX) on breath hydrogen (a marker of intestinal fermentation), plasma SCFAs, gut hormones, insulin and blood glucose concentrations as well as appetite in RYGB patients. METHOD: Eight RYGB patients were studied on two occasions before and ~8 months after surgery using a cross-over design. Each patient received 300 ml orange juice containing 25 g inulin or an equicaloric load of 15.5 g MDX after an overnight fast followed by a fixed portion snack served 3 h postprandially. Blood samples were collected over 5 h and breath hydrogen measured as well as appetite assessed using visual analog scales. RESULTS: Surgery increased postprandial secretion of GLP-1 and PYY (P ≤ 0.05); lowered blood glucose and plasma insulin increments (P ≤ 0.05) and reduced appetite ratings in response to both inulin and MDX. The effect of inulin on breath hydrogen was accelerated after surgery with an increase that was earlier in onset (2.5 h vs. 3 h, P ≤ 0.05), but less pronounced in magnitude. There was, however, no effect of inulin on plasma SCFAs or plasma GLP-1 and PYY after the snack at 3 h, neither before nor after surgery. Interestingly, inulin appeared to further potentiate the early-phase glucose-lowering and second-meal (3-5 h) appetite-suppressive effect of surgery with the latter showing a strong correlation with early-phase breath hydrogen concentrations. CONCLUSION: RYGB surgery accelerates large intestinal fermentation of inulin, however, without measurable effects on plasma SCFAs or plasma GLP-1 and PYY. The glucose-lowering and appetite-suppressive effects of surgery appear to be potentiated with inulin.
Asunto(s)
Derivación Gástrica , Insulinas , Humanos , Inulina/farmacología , Apetito , Proyectos Piloto , Glucemia , Estudios Cruzados , Estudios Prospectivos , Péptido YY , Péptido 1 Similar al Glucagón , PercepciónRESUMEN
Pinkeye is a highly contagious disease of goats with different aetiologies. Surveys in Lao PDR have identified eye lesions typical of pinkeye as a common condition, however, this has not been confirmed diagnostically, and the responsible pathogens have not been identified. A matched case-control study was implemented in 70 goat holdings from Savannakhet province, Lao PDR, to detect agents causing pinkeye and conduct phylogenetic analysis of the identified pathogens. Fifty eye swabs from goats with infected eyes (cases) and 50 paired samples from unaffected cohorts (controls) were collected from 25 holdings. Samples were tested using quantitative PCR assays targeting known pinkeye pathogens at the genus and species levels. The prevalence of pathogens in case and control goats was as follows: Mycoplasma conjunctivae (94% and 74% respectively, P = 0.006, OR = 5.5), Chlamydia pecorum (4%, 10%), Moraxella ovis (30%, 30%), Moraxella bovis (0%, 0%) and Moraxella bovoculi (0%, 0%). M. conjunctivae was present in a high proportion of goats in both groups revealing that Lao goats are carriers of M. conjunctivae. However, the mean log10 genome copy number/µL of DNA extract was significantly higher in case goats than control goats (P < 0.05). Thus, M. conjunctivae is likely the principal causative agent of pinkeye in Lao goats with carrier status converting to clinical infection following corneal damage or other causative factors. M. conjunctivae detected in samples from different goats and districts showed low genetic diversity. Identifying the causes of pinkeye in Lao goats will assist in designing appropriate treatment and control strategies.
Asunto(s)
Enfermedades de las Cabras , Cabras , Filogenia , Animales , Enfermedades de las Cabras/microbiología , Enfermedades de las Cabras/epidemiología , Estudios de Casos y Controles , Laos/epidemiología , Conjuntivitis/veterinaria , Conjuntivitis/microbiología , Conjuntivitis/epidemiología , Prevalencia , Moraxella/aislamiento & purificación , Moraxella/genética , Mycoplasma conjunctivae/genética , Mycoplasma conjunctivae/aislamiento & purificación , Chlamydia/aislamiento & purificación , Chlamydia/genética , Chlamydia/clasificación , Infecciones por Mycoplasma/veterinaria , Infecciones por Mycoplasma/microbiología , Infecciones por Mycoplasma/epidemiologíaRESUMEN
BACKGROUND: Close resection margins < 5 mm (CM) or extra capsular extent at the lymph nodes (ECE) impair the prognosis of patients with squamous cell cancer of the head and neck (SCCHN) scheduled for adjuvant radiochemotherapy. We conducted a multicenter phase II study to investigate toxicity and efficacy of additional cetuximab administered concomitantly and as maintenance for the duration of 6 months following adjuvant radiochemotherapy., Ppreliminary results on feasibility and acute toxicity on skin and mucosa are presented in this article. METHODS: Patients with SCCHN following CM resection or with ECE were eligible for the study. In all, 61.6 Gy (1.8/2.0/2.2 Gy, days 1-36) were administered using an integrated boost intensity-modulated radiotherapy (IMRT) technique. Cisplatin (20 mg/m(2), days 1-5 and days 29-33) and 5-fluorouracil (5-FU) as continuous infusion (600 mg/m(2), days 1-5 + days 29-33) were given concurrently. Cetuximab was started 7 days prior to radiochemotherapy at 400 mg/m(2) followed by weekly doses of 250 mg/m(2). Maintenance cetuximab began after radiochemotherapy at 500 mg/m(2) every 2 weeks for 6 months. RESULTS: Of the 55 patients (46 male, 9 female, mean age 55.6, range 29-70 years) who finished radiochemotherapy, 50 were evaluable for acute toxicity concerning grade III/IV toxicities of skin and mucosa. Grade 3-4 (CTC 3.0) mucositis, radiation dermatitis, and skin reactions outside the radiation portals were documented for 46, 28, and 14 % of patients, respectively. One toxic death occurred (peritonitis at day 57). Cetuximab was terminated in 5 patients due to allergic reactions after the first application. In addition, 22 % of patients discontinued cetuximab within the last 2 weeks or at the end of radiochemotherapy. Of patients embarking on maintenance treatment, 80 % were still on cetuximab at 3 months and 63 % at 5 months. Concurrent and maintenance treatment with cetuximab could be administered as scheduled in 48 % of patients. CONCLUSION: Adjuvant radiochemotherapy with concomitant and maintenance cetuximab is feasible and acute toxicities are within the expected range. Compliance within the first 3-5 months is moderate.